Chesley Taft & Associates’s Allergan plc AGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2017
Q4
Sell
-4,026
Closed -$825K 288
2017
Q3
$825K Sell
4,026
-9,033
-69% -$2.1M 0.07% 188
2017
Q2
$3.17M Buy
13,059
+3,482
+36% +$818K 0.29% 89
2017
Q1
$2.29M Sell
9,577
-230
-2% -$53.6K 0.22% 101
2016
Q4
$2.06M Sell
9,807
-21,362
-69% -$4.43M 0.2% 100
2016
Q3
$7.18M Buy
31,169
+17,151
+122% +$4.19M 0.72% 44
2016
Q2
$3.24M Sell
14,018
-186
-1% -$42.9K 0.33% 82
2016
Q1
$3.81M Sell
14,204
-42
-0.3% -$12K 0.4% 70
2015
Q4
$4.45M Sell
14,246
-4,206
-23% -$1.25M 0.47% 69
2015
Q3
$5.01M Buy
18,452
+275
+2% +$84.5K 0.55% 61
2015
Q2
$5.52M Buy
18,177
+201
+1% +$60K 0.56% 61
2015
Q1
$5.35M Buy
17,976
+10,166
+130% +$2.9M 0.55% 61
2014
Q4
$2.01M Buy
7,810
+35
+0.5% +$8.75K 0.2% 108
2014
Q3
$1.88M Buy
7,775
+125
+2% +$28K 0.2% 107
2014
Q2
$1.71M Buy
7,650
+50
+0.7% +$10.4K 0.18% 112
2014
Q1
$1.56M Sell
7,600
-80
-1% -$15.8K 0.17% 116
2013
Q4
$1.29M Sell
7,680
-120
-2% -$18.8K 0.13% 140
2013
Q3
$1.12M Sell
7,800
-100
-1% -$13.3K 0.12% 148
2013
Q2
$997K Buy
+7,900
New +$894K 0.12% 149

Other funds holding AGN

Chesley Taft & Associates's AGN Position: Q4 2017 in Review

Chesley Taft & Associates sold out of Allergan plc (AGN) in Q4 2017, closing a stake of 4,026 shares — an estimated $825K sold.

Chesley Taft & Associates first reported a position in AGN in Q2 2013 and held it in 18 quarters. The position peaked at $7.18M in Q3 2016. 1,048 funds tracked by Wall St. Rank hold AGN as of Q4 2017.

  • Chesley Taft & Associates reported no remaining Allergan plc position as of Q4 2017 after selling out during the quarter.
  • Chesley Taft & Associates sold 4,026 Allergan plc shares in Q4 2017, an estimated $825K.
  • Chesley Taft & Associates first reported a position in Allergan plc in Q2 2013 and held it in 18 quarters.
  • Chesley Taft & Associates's Allergan plc position peaked at $7.18M in Q3 2016.
  • 1,048 funds tracked by Wall St. Rank held Allergan plc as of Q4 2017.

Based on Chesley Taft & Associates's 13F filing for Q4 2017, filed 10 Jan 2018.